Designed for genetic testing in hereditary breast and ovarian cancers
The Devyser HBOC gene panel has been developed with an integrative approach towards the varying literature and expert recommendations for follow-up after negative BRCA testing. It can also be employed as a first-line protocol simultaneously with BRCA1 and BRCA2, extending the screening by an additional 12 genes. Its purpose is to pinpoint mutations in genes with a recognised connection to the development of breast and ovarian cancers.
Quick and easy implementation
With ready-to-use reagents, less than 45 minutes hands-on time and customised data interpretation software, it is a good match for laboratories of any size. The targeted sequencing approach combined with uniform coverage of target regions maximises the output of relevant sequencing data in every run.
Identify variants to guide testing of at-risk relatives
Genetic testing of these genes may help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing of at-risk relatives. This test is specifically designed for heritable germline mutations.
